Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274345 | 0.88 | L3MBTL1 (0.53) | HPGDNPSR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL25040676 | 0.88 | L3MBTL1 (0.53) | HPGDNPSR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL14860956 | 0.85 | HPGD (0.49) | HPGDNPSR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL7519591 | 0.84 | GAA (0.60) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL8862940 | 0.84 | GAA (0.60) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL8862746 | 0.84 | GAA (0.60) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL8862856 | 0.84 | GAA (0.60) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL2743018 | 0.82 | HPGD (0.61) | HPGDNPSR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL14322882 | 0.82 | HPGD (0.46) | HPGDNPSR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL18355157 | 0.80 | HPGD (0.53) | HPGDNPSR1L3MBTL1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216445-A1 | CXCR4 INHIBITING CARRIERS FOR NUCLEIC ACID DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-9545453-B2 | CXCR4 inhibiting carriers for nucleic acid delivery | WAYNE STATE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20140243397-A1 | CXCR4 INHIBITING CARRIERS FOR NUCLEIC ACID DELIVERY | WAYNE STATE UNIVERSITY | 2014-08-28 | — | — | US | disclosed |
| WO-2013056250-A2 | CXCR4 INHIBITING CARRIERS FOR NUCLEIC ACID DELIVERY | WAYNE STATE UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243397-A1 | CXCR4 INHIBITING CARRIERS FOR NUCLEIC ACID DELIVERY | CXCL12, CXCR4, CXCR2 | HPGD 1488/4885NPSR1 285/4885L3MBTL1 1672/4885 |
| US-20170216445-A1 | CXCR4 INHIBITING CARRIERS FOR NUCLEIC ACID DELIVERY | CXCL12, CXCR4, CXCR2 | HPGD 1451/4885NPSR1 318/4885L3MBTL1 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.